Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

6:16 AM ET 8-K
Leadership Change Tutor Perini Corp TPC

Tutor Perini Leadership Change

Sidney Feltenstein, a member of the Board of Directors since 2013, has resigned effective October 30, 2026. The resignation follows a reduction in the beneficial ownership of Ronald N. Tutor's affiliated trusts below the 11.25% threshold required to maintain a board designee under a 2008 Shareholders Agreement.

6:16 AM ET 8-K
Business Update Braemar Hotels & Resorts Inc. BHR

Braemar Hotels & Resorts Business Update

Braemar Hotels & Resorts released preliminary, unaudited interim financial and operating metrics for its continuing portfolio for the trailing twelve months ended August 31, 2026. The portfolio reported total revenue of $385.2 million and Hotel EBITDA of $90.4 million, with a weighted average RevPAR of $334. These figures are current estimates and remain subject to revision as the company completes its quarterly financial closing procedures.

Term
TTM Ended August 31, 2026
6:16 AM ET 8-K
Business Update Hyperscale Data, Inc. GPUS

Hyperscale Data Business Update

Hyperscale Data, Inc. has amended its at-the-market (ATM) issuance sales agreement to reduce the maximum offering capacity from $300 million to $100 million. The company has raised approximately $49.8 million to date under the program and stated the reduction is intended to limit equity dilution as management believes the stock is undervalued.

Counterparty
Spartan Capital Securities, LLC
6:15 AM ET 8-K
Financial Results Unitedhealth Group Inc UNH

Unitedhealth Group Financial Results

UnitedHealth Group reported third quarter 2026 revenues of $112.7 billion and adjusted earnings of $4.69 per share. The company raised its full-year 2026 adjusted earnings outlook to at least $20.50 per share, citing strong medical cost management and operational discipline.

Term
Q3 2026

“Our third quarter results reflect the discipline and execution our teams are bringing to every part of our business, as we continue evolving UnitedHealth Group to deliver a simpler, more supportive experience for patients and the clinicians who care for them.”

Stephen Hemsley, chief executive officer of UnitedHealth Group
6:12 AM ET 8-K
Financial Results Unity Bancorp Inc UNTY

Unity Bancorp Financial Results

Unity Bancorp reported Q3 2026 net income of $17.4 million, or $1.70 per diluted share, driven by robust loan and deposit growth and a $2.5 million tax benefit from investment tax credits. Net interest income rose to $34.3 million as the net interest margin expanded to 4.67%.

Term
Q3 2026

“We are pleased to report another strong quarter for Unity, highlighted by net income of $17.4 million, or $1.70 per diluted share, and continued momentum across our core banking franchise. Loan and deposit growth remained robust, net interest income increased, net interest margin expanded, and asset quality improved meaningfully during the quarter.”

James A. Hughes, CEO

“Looking ahead, we are confident in Unity's long-term prospects as we prepare for the planned leadership transition next year to our President, George Boyan. Mr. Boyan has been deeply involved in every aspect of our strategic and operational execution, and I am confident that Unity is well-positioned for continued success under his leadership.”

James A. Hughes, CEO
6:11 AM ET 8-K
Business Update Enovix Corp ENVX

Enovix Business Update

Enovix reported preliminary Q3 2026 revenue of $11.0 million, exceeding its guidance range of $9 million to $10 million, driven by a 48% growth in its drone pipeline to $150 million. The company is investing $19 million to double manufacturing capacity at its Korean plant to meet defense demand and has appointed Steve Bakos as its first Chief Revenue Officer.

“We are focusing on moving our $216 million drone, defense and industrial pipeline forward into design wins, purchase orders and shipments. The added Korean manufacturing capacity will enable timely delivery of those orders, which in the first part of Q4’26 have already exceeded our Q3’26 total revenue.”

Ryan Benton, Interim CEO
6:11 AM ET 8-K
Capacity Expansion Ttm Technologies Inc TTMI

Ttm Technologies Capacity Expansion: $400M Investment

TTM Technologies announced a $400 million incremental investment to expand manufacturing capacity across four facilities in China and its facility in Penang, Malaysia. The expansion uses a "rapid-ramp" brownfield approach to scale advanced interconnect technology for AI data center infrastructure and hyperscalers. This investment is in addition to the company's previously disclosed $1.2 billion commitment for the 2025-2029 period.

Value
$400M
Term
2025-2029
6:10 AM ET 8-K
Loan & Debt Co-Diagnostics, Inc. CODX

Co-Diagnostics $3.1M Debt Financing with J.J. Astor & Co.

Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for an aggregate principal funding amount of up to $3.1 million. The initial funding of $2.1 million resulted in a promissory note with an original principal amount of $2.835 million, reflecting a 1.35x factor rate, and is secured by substantially all of the company's assets.

Value
$3.1M
Counterparty
J.J. Astor & Co.
Term
30 weeks
6:10 AM ET 8-K
Leadership Change Bausch & Lomb Corp BLCO

Bausch & Lomb Leadership Change

Bausch + Lomb announced that CEO Brent Saunders has mutually agreed with the Board to depart the company and the Board effective October 12, 2026. Thomas J. Appio, the current Chairman of the Board and CEO of parent company Bausch Health, has been appointed interim CEO. In connection with his departure, Mr. Saunders will receive a $75.5 million lump-sum cash payment and forfeit all outstanding equity awards.

6:10 AM ET 10-Q
Financial Results Dominos Pizza Inc DPZ

Dominos Pizza Q3 2026 Results: Net Income $152M, Up 9.2% YoY

Domino’s Pizza, Inc. reported total revenues of $1.19 billion for the third quarter of 2026, a 3.4% increase over the prior year, driven primarily by supply chain growth. Net income rose to $152.2 million, or $4.60 per diluted share, while the company's balance sheet reflects a significant shift in debt classification with $1.33 billion moved to current liabilities.

Key figure
Net income $152M · +9.2% YoY
6:07 AM ET 8-K
Business Update Ssr Mining Inc. SSRM

Ssr Mining Business Update

SSR Mining Inc. announced the results of a Technical Report Summary (TRS) for its Marigold Complex in Nevada, prepared in accordance with SEC Subpart 1300 of Regulation S-K. The report provides updated technical and operational data for the mining complex, including mineral resource and reserve estimates as of May 1, 2026. This filing serves as a formal disclosure of the project's current status and long-term economic potential to investors.

6:07 AM ET Form 4
Insider Selling Sea Ltd SE

Sea CCO and GC Yanjun Wang Sells $186K of Stock

Yanjun Wang, CCO and GC, sold 1,941 shares of Sea Ltd at $94.82 to $96.10 a share (average $95.59) in 4 transactions, worth $186K in total between Oct 9, 2026 and Oct 12, 2026. Shares held after the trade: 81,800 (-0.8%).

Value
$186K
Shares
1,941
Average price
$95.59
Role
CCO and GC
Holding change
-0.8%
Trade date
Oct 9, 2026 to Oct 12, 2026
6:06 AM ET 8-K
Financial Results Dominos Pizza Inc DPZ

Dominos Pizza Financial Results

Domino’s Pizza reported third quarter 2026 financial results, featuring global retail sales growth of 3.2% and the addition of 175 net new stores globally. U.S. same-store sales grew 0.3% while income from operations increased 8.3% compared to the prior year period. This quarter marked the first results under new CEO Joe Jordan, who emphasized a focus on franchisee profitability and market share gains.

Term
Q3 2026

“As I step into the CEO role, I am honored to lead Domino’s and build on the competitive advantages that have long set us apart: our iconic brand, best-in-class franchise system, global scale and proven operating capabilities. Our opportunity now is to capitalize on those strengths by getting even closer to our customers, helping our franchisees grow their profitability and turning our best performance into our everyday performance. By advancing winning ideas faster and executing them with greater clarity, speed and consistency, we can earn more occasions, continue gaining market share and create meaningful long-term value for shareholders. Domino’s has always been at its best when we are a step ahead. That mindset has helped us set the pace for the industry before, and it’s how we’ll push ourselves to do it again. I believe our next chapter will be our strongest yet.”

Joe Jordan, Domino’s Chief Executive Officer
6:05 AM ET 8-K
Loan & Debt SS Innovations International, Inc. SSII

SS Innovations International $21M Debt Financing with institutional investor

SS Innovations International entered into a Securities Purchase Agreement with an institutional investor for the issuance of a secured convertible promissory note in the principal amount of $21.025 million. The note carries an 8.75% interest rate and is secured by the company's intellectual property and other assets, excluding its Indian operating subsidiary. Proceeds will be used for general corporate purposes, and the note is convertible into common shares at a discount to the market price.

Value
$21M
Counterparty
institutional investor
Term
36 months
6:05 AM ET 8-K
Other 8-K Filing Sino Green Land Corp. SGLA

Sino Green Land Other 8-K Filing

Sino Green Land Corporation entered into a Debt-to-Equity Conversion Agreement to settle $2,400,528 in unsecured, non-interest-bearing demand loans. The company issued 4,801,056 shares of common stock at a fixed price of $0.50 per share to several creditors, including controlling persons, to fully extinguish the debt.

Counterparty
Luo Xiong, Wo Kuk Ching, Empower International Trading Sdn. Bhd., and Xu Liming
6:05 AM ET 8-K
Partnership Humana Inc HUM

Humana Partnership with BlackRock, Inc. Worth $2.8B

Humana entered into a new strategic joint venture with BlackRock to manage and operate nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake held by Welsh, Carson, Anderson & Stowe (WCAS) for approximately $2.8 billion, providing Humana with a lower cost of capital and enhanced balance sheet efficiency by removing existing put option liabilities.

Value
$2.8B
Counterparty
BlackRock, Inc.
Term
through 2033
6:03 AM ET 8-K
Shareholder Meeting IX Acquisition Corp. IXAQF

IX Acquisition Shareholder Meeting

IX Acquisition Corp. held an extraordinary general meeting where shareholders approved the Fifth Extension Amendment Proposal and ratified the company's auditors. In connection with the vote, 435,000 Class A ordinary shares were tendered for redemption by shareholders.

6:03 AM ET 8-K
M&A Deal IonQ, Inc. IONQ

IonQ Signs $1.15B M&A Deal with Elisity, Inc.

IonQ has entered into a definitive agreement to acquire Elisity, Inc., a Zero Trust security company, in an all-stock transaction valued at up to $1.3 billion including earnouts. The deal consists of $1.15 billion in closing consideration plus up to $150 million in revenue-based earnout consideration through January 2028. The acquisition aims to combine IonQ's quantum cryptography capabilities with Elisity's Zero Trust platform to address emerging quantum-era cybersecurity threats.

Value
$1.15B
Counterparty
Elisity, Inc.

“With Elisity and its team as part of IonQ, we will be well positioned to help customers protect critical infrastructure and enterprise networks throughout the transition to the quantum era. As I said first, Q-Day is coming much faster than predicted. IonQ is offering its customers a vertically integrated full-stack quantum platform across quantum computing, networking, sensing and cybersecurity. Just as adding SkyWater Technology expanded IonQ’s capabilities in chip design, fabrication and packaging, Elisity will bring proven enterprise policy enforcement scale and deployment experience to our quantum security strategy and will give IonQ a strong growth platform to serve customers and create value for our shareholders.”

Niccolo de Masi, Chairman and CEO of IonQ

“Our customers need to prioritize post-quantum cryptography initiatives while securing existing assets to keep essential operations running. With IonQ, we will be optimally positioned to partner with them to modernize their crypto-agility programs, accelerate post-quantum cryptography capabilities while advancing their holistic Zero Trust posture and deploy hybrid-cybersecurity solutions today that are prepared for the quantum future.”

James Winebrenner, CEO of Elisity
6:03 AM ET 8-K
Business Update High Roller Technologies, Inc. ROLR

High Roller Technologies Business Update

High Roller Technologies issued a clarification regarding an erroneous marketing email that suggested a launch date for its prediction markets product during the week of October 12, 2026. The company clarified that no specific launch date has been set, though it still expects to launch the product sometime in October 2026.

6:03 AM ET 8-K
Business Update ArriVent BioPharma, Inc. AVBP

ArriVent BioPharma Business Update

ArriVent BioPharma announced the dosing of the first patient in its U.S. Phase 1 clinical trial of ARR-002, a potential first-in-class dual-target antibody-drug conjugate (ADC). The trial is evaluating the safety and efficacy of the candidate in patients with advanced or metastatic ovarian and endometrial cancer.

6:03 AM ET 10-Q
Financial Results Zhanling International Ltd ZLME

Zhanling International Q1 2026 Results: Net Loss of $6.6K, Loss Narrows

Zhanling International Ltd reported a net loss of $6,597 for the three months ended August 31, 2026, compared to a loss of $8,126 in the prior year period. The company remains a shell entity with no revenue, an accumulated deficit of $475,150, and is currently seeking a merger or acquisition target.

Key figure
Net loss $6.6K
6:03 AM ET 8-K
Leadership Change CCO Holdings Capital Corp CHTR

CCO Holdings Capital Leadership Change

Charter Communications announced that Adam Ray has stepped down as Executive Vice President and Chief Commercial Officer, effective October 12, 2026. Mr. Ray will remain with the company in a non-executive advisory capacity through December 31, 2026, and will receive severance benefits and continued equity vesting in recognition of his 21 years of service.

6:03 AM ET 8-K
Investor Meeting Drilling Tools International Corp DTI

Drilling Tools International Investor Meeting

Drilling Tools International Corporation has engaged a Norwegian investment bank to arrange a series of fixed income investor meetings in the Nordic market starting October 14, 2026. These meetings are in preparation for a contemplated U.S. dollar denominated senior secured bond issue intended to finance the acquisition of Saltire Energy Limited and refinance existing debt.

6:03 AM ET 8-K
Business Update Immucell Corp ICCC

Immucell Business Update

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2026, reporting total sales of $8.0 million, a 46% increase over the same period in 2025. The growth was driven by strong performance across its product portfolio, including a 51% increase in Tri-Shield sales and a 27.8% increase in total sales for the first nine months of the year.

Term
Q3 2026
6:03 AM ET 8-K
Business Update BridgeBio Pharma, Inc. BBIO

BridgeBio Pharma Business Update

BridgeBio Pharma announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia and granted it Priority Review. The FDA has assigned a PDUFA target action date of February 4, 2027, for the potential approval of what would be the first oral therapy for this condition. The filing is supported by Phase 3 PROPEL 3 data showing significant improvements in annualized height velocity and body proportionality.

Counterparty
FDA
6:03 AM ET 8-K
Clinical Trial Data Zenas BioPharma, Inc. ZBIO

Zenas BioPharma Clinical Trial Data

Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.

6:03 AM ET 8-K
Nasdaq/NYSE Compliance Notice Clearone Inc CLRO

Clearone Nasdaq/NYSE Compliance Notice

ClearOne, Inc. received a staff determination letter from Nasdaq on October 8, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders' equity requirement. As a result, Nasdaq has determined to delist the company's common stock, though ClearOne intends to appeal this decision before a Nasdaq Hearings Panel to stay the delisting process.

Counterparty
Nasdaq
6:03 AM ET 8-K
Loan & Debt Mitesco, Inc. MITI

Mitesco Debt Financing Update with ZSP Capital, LLC

Mitesco, Inc. entered into a $25,000 10% Original Issue Discount Convertible Promissory Note with ZSP Capital, LLC, maturing in 12 months. The note is convertible into common stock at $0.15 per share and was issued alongside 2 million shares of restricted common stock granted to individuals for project assistance. Additionally, Dr. Jordan Ballencic resigned from the Board of Directors effective October 8, 2026.

Counterparty
ZSP Capital, LLC
Term
12 months
6:03 AM ET 8-K
Leadership Change Evernorth Holdings Inc. XRPN

Evernorth Holdings Leadership Change

Evernorth Holdings Inc. appointed Hugo Jeandesboz, formerly of Coinbase Asset Management, as its new Chief Investment Officer to lead the company's XRP treasury strategy. The filing also corrected a clerical error regarding the number of Class A shares issued to PIPE delayed funding subscribers at the closing of its business combination, increasing the count to 1,078,613 shares.

6:02 AM ET 8-K
Shareholder Meeting MiniMed Group, Inc. MMED

MiniMed Group Shareholder Meeting

MiniMed Group, Inc. held its 2026 Annual Meeting of Stockholders on October 9, 2026, where shareholders approved all four proposals. Key outcomes included the election of four Class I directors to serve until 2029, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation (say-on-pay) on an annual frequency.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.